International Myeloma Society Annual Meeting: Key Data and Guideline Updates in Multiple Myeloma

Pharmacy Times® is headed to Toronto, Canada for the 2025 International Myeloma Society (IMS) Annual Meeting to cover emerging data on novel agents and interview the key experts driving research and innovation. The meeting will spotlight new data and expert perspectives that are expected to shape the evolving standards of care in multiple myeloma (MM), with particular attention to novel agents, treatment strategies, and risk-adapted management approaches.

Toronto, Canada | Image Credit: © rabbit75_fot - stock.adobe.com

Updates in Multiple Myeloma

• The upcoming core session will bring together leading experts to explore how patient-specific factors influence treatment decisions in newly diagnosed MM. The session will cover genetic and biological risk factors in risk assessment, followed by presentations addressing transplant eligibility based on age or fitness, strategies for managing high-risk disease, and tailoring therapy for frail patients.
• A session on updates to the International Myeloma Working Group (IMWG) guidelines will provide key updates on collaborative efforts shaping global standards in MM care. The session will highlight the latest revisions to the IMWG/IMS Uniform Response Criteria, offering updates that will refine disease assessment, guide clinical decision-making, and influence future research directions.
• The session on infection risk with T-cell engagers in MM will examine one of the most pressing challenges in the era of novel immunotherapies. Expert presentations will explore underlying factors that influence infection risk in MM, with a focused look at the unique risks associated with T-cell engaging therapies.

Key Expert Interviews

• Matthew Lei, PharmD, BCOP, clinical pharmacy specialist in lymphoma at Massachusetts General Hospital, Boston, is presenting a poster on the initial results of the phase 2 EPIC trial (NCT06138275),¹ which is evaluating elranatamab (Elrexfio; Pfizer) as consolidation therapy following idecabtagene vicleucel (ide-cel, Abecma; Celgene Corporation/Bristol Myers Squibb) in patients with relapsed/refractory MM (R/R MM).
• Karen Rodriguez-Lorenc, MD, VP, Therapeutic Area Lead Hemato-Oncology at Regeneron, will discuss a presentation on next-generation immunotherapies for R/R MM, with a focus on integrating costimulatory bispecific antibody signaling.
• Paula Rodriguez Otero, specialist in hematology and hemotherapy and medical coordinator of the Central Unit for Clinical Trials, will be presenting data on the safety and efficacy of linvoseltamab (Lynozyfic; Regeneron) in patients with high-risk smoldering MM.

REFERENCES

1. Elranatamab in R/​R multiple myeloma. Clinicaltrials.gov. Updated August 13, 2025. Accessed September 16, 2025. https://clinicaltrials.gov/study/NCT06138275